Conformational basis for the activation of adenylate cyclase by adenosine
- 1 June 1977
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 74 (6), 2194-2198
- https://doi.org/10.1073/pnas.74.6.2194
Abstract
The ability of adenosine to stimulate adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] and increase cyclic[c]AMP levels has important biochemical consequences. These include suppression of immune responses and cardiovascular effects. Recent investigations involving the ability of adenosine and adenosine analogs to stimulate adenylate cyclase provided experimental data that appear to be correlated with the ability of adenosine and analogs of adenosine to exist in the glycosidic high anti conformation. 9-.beta.-D-Arabinofuranosyladenine, which is not stable in the high anti conformation, is inactive as a stimulator of adenylate cyclase. 2''-Deoxyadenosine is not stable in the high anti conformation, but its instability may be significantly decreased by intramolecular adjustments promoted by receptor or active site interactions. 2''-Deoxyadenosine does not activate adenylate cyclase in lymphocytes when ATP is the substrate but is able to activate adenylate cyclase when 2-fluoro ATP is the substrate. The inability of certain analogs of adenosine, with bulky groups substituted for H at the 8 position of the adenine base, to activate adenylate cyclase and increase lymphocyte or cardiac cell cAMP levels is consistent with the designation of the high anti conformation as being the conformation required for activation of adenylate cyclase. An understanding of the glycosidic conformation required by the extracellular adenosine receptor of the adenosine molecule provides the basis for designing nucleoside analogs of adenosine that will exert a desired effect on cAMP levels. Avoidance of unwanted immunosuppressive or cardiotoxic effects can be arranged by structural changes that prohibit the high anti conformation. There are several aspects to the toxicity associated with an excess of adenosine. The enzymes adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) and adenosine kinase (ATP:adenosine-5''-phosphotransferase, EC 2.7.1.20) compete for adenosine. At higher concetrations of adenosine, adenosine deaminase dominates and protects the body from the effects of an excess of adenosine.This publication has 73 references indexed in Scilit:
- Cyclic nucleotides in disease; On the biochemical etiology of hypertensionLife Sciences, 1975
- CARDIOVASCULAR EFFECTS OF NUCLEOSIDE ANALOGSAnnals of the New York Academy of Sciences, 1975
- Synthesis and coronary vasodilating activity of 2-substituted adenosines.CHEMICAL & PHARMACEUTICAL BULLETIN, 1975
- Molecular form of adenosine deaminase in severe combined immunodeficiencyBiochemical and Biophysical Research Communications, 1974
- Absence of erythrocyte adenosine deaminase associated with severe combined immunodeficiencyThe Journal of Pediatrics, 1974
- Evidence for the control of pyrimidine biosynthesis in tissue minces by purinesBiochemical and Biophysical Research Communications, 1974
- Adenosine-elicited accumulation of cyclic AMP in brain slices: Potentiation by agents which inhibit uptake of adenosineLife Sciences, 1974
- Pyrimidine Starvation Induced by Adenosine in Fibroblasts and Lymphoid Cells: Role of Adenosine DeaminaseScience, 1973
- Inhibitor of pyrimidine metabolism from tumor tissuesBiochemical and Biophysical Research Communications, 1973
- Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosineLife Sciences, 1972